Protara Therapeutics Inc. Company Profile
NASDAQ: TARAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Protara Therapeutics at a glance
Protara Therapeutics Inc. (NASDAQ: TARA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in New York, NY. Protara Therapeutics is led by Mr. Jesse Shefferman and employs about 46 people. The company's shares have traded publicly since 2014.
At a market capitalization of $156.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001359931, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Protara Therapeutics do?
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Business description based on the company's public filings.
Company information
- Legal name
- Protara Therapeutics Inc.
- Ticker
- NASDAQ: TARA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Jesse Shefferman
- Employees
- 46
- Headquarters
- 345 Park Avenue South, New York, NY, United States
- Phone
- 646 844 0337
- Website
- protaratx.com
- IPO year
- 2014
- Market cap
- $156.60M
- SEC CIK
- 0001359931
Companies similar to Protara Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRDLCardiol Therapeutics Inc. Class A | 1.30 | -1.52% | $157.97M | vs TARA |
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | 0.00% | $151.87M | vs TARA |
| CHRSCoherus Oncology Inc. | 1.07 | +5.94% | $165.32M | vs TARA |
| IPHAInnate Pharma S.A. ADS | 1.48 | -2.63% | $165.32M | vs TARA |
| VYGRVoyager Therapeutics Inc. | 2.37 | -4.05% | $146.03M | vs TARA |
| MOLNMolecular Partners AG ADR | 3.81 | 0.00% | $145.94M | vs TARA |
| ARMPArmata Pharmaceuticals Inc. | 3.86 | +1.31% | $143.52M | vs TARA |
| AVXLAnavex Life Sciences Corp. | 1.54 | +0.65% | $142.75M | vs TARA |